Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright? Hims & Hers (HIMS 4.71%) stock has been on a roller coaster about the availability of GLP-1s to its customers. However, the focus on one treatment may miss the company's strategy. In this video, Travis Hoium shows why Hims & Hers will be fine with or without GLP-1s. *Stock prices used were end-of-day prices of Oct. 7, 2024. The video was published on Oct. 8, 2024. ...

Look beyond the stock price at the business when shares are volatile. When the stock market is volatile and share prices tumble, opportunities arise to search for great businesses with stocks temporarily trading at bargain levels. When this happens, investors with a multiyear buy-and-hold strategy can shrewdly add such stocks to their portfolio while others sit on the sidelines. It's true that just because a stock is trading lower doesn't necessarily mean it has become a better buy. Sometimes, stocks trade ...

Consistently investing even moderate sums can grow your portfolio with time. Bull and bear markets come and go, and along with them come short-term investment opportunities. However, investors with a long-term buy-and-hold perspective can find opportunities in any market environment. And those opportunities don't always require a lot of available cash to tap into. Even with a more modest stash of cash -- say $500 -- to invest, you can find plenty of companies to put some or all of that amount into to benefi ...

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 9, 2024S&P SmallCap 600 Ad ...

Hims & Hers may not be hurt by GLP-1 news the way investors think. Shares of Hims & Hers (HIMS -9.60%) fell as much as 15% on Thursday after news that Eli Lilly's (LLY -0.62%) GLP-1 drug was taken off the shortage list by the FDA. This could impact Hims & Hers' GLP-1 strategy, but it may not have the impact you think. In this video, Travis Hoium covers the day's news and why this isn't a big deal for investors. *Stock prices used were end-of-day prices of Oct. 3, 2024. The video was published on Oct. 3, 202 ...

Core Viewpoints - Hims & Hers Health shares dropped significantly after the FDA removed Eli Lilly's weight-loss drugs from its shortage list, impacting the company's ability to produce compounded versions [1] - The FDA's decision prohibits the production of compounded copycat drugs, which Hims & Hers has benefited from due to limited availability of original obesity medicines [1] - Hims & Hers shares fell 11 4% to $16 77 on Thursday, despite a year-to-date gain of nearly 90% [1] Company Performance - Hims & Hers Health shares experienced a sharp decline, dropping 11 4% to $16 77 in Thursday afternoon trading [1] - The company's shares have gained close to 90% since the start of the year, despite the recent drop [1] - Trading volume for Hims & Hers Health was 20 132 million on October 3, 2024 [2] Regulatory Impact - The FDA's removal of Eli Lilly's weight-loss drugs from its shortage list affects Hims & Hers' ability to produce compounded versions [1] - The FDA allows compounded drugs when original drugs are hard to obtain, but the latest decision restricts this for Eli Lilly's drugs [1] - This regulatory change could negatively impact Hims & Hers, which has benefited from the limited availability of certain obesity medicines [1] Market Context - Eli Lilly's weight-loss drugs, Mounjaro and Zepbound, are no longer on the FDA's shortage list, impacting competitors like Hims & Hers [1] - Earlier in August, Hims & Hers shares also declined after Eli Lilly announced cost-saving measures for its weight-loss drugs [1]

The healthcare company will be making more of the product it sells. Shares of healthcare company Hims & Hers Health (HIMS 2.85%) jumped as much as 23.9% this week after news of closing a large acquisition. According to data provided by S&P Global Market Intelligence, shares are up 18.3% for the week as of 2:30 p.m. ET. Hims & Hers gets deeper into compounding The biggest news was Hims & Hers issuing 976,341 shares of common stock to acquire Nivagen Pharmaceuticals, which does business as MedisourceRX. The c ...

Hims & Hers Health, Inc.'s (HIMS) investors are encountering some short-term losses from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have plunged 32.1% in the past three months, underperforming the industry's 11.4% gain. In the same time frame, the stock underperformed the sector and S&P 500's 4.7% and 2.7% growth, respectively. Two major developments from HIMS in recent months include the announcement of its second-quarter 2024 results (in August) and the addition ...

Sales growth could accelerate now that it provides lower-cost, weight-management drugs. If you'd like to become a billionaire, paying attention to how other billionaires invest is a sensible way to get started. Everyday investors can easily keep tabs on billionaire stock purchases because the U.S. Securities and Exchange Commission (SEC) makes them disclose their trading activity every three months. In the latest round of disclosures, it's clear that a handful of funds run by billionaire investors bought sh ...

PM Images/DigitalVision via Getty Images Markets appear to have shaken off the fears stemming from U.S. recession talk and the unwinding of the Japan carry trade, but a number of stocks still remain well off their recent highs. Hims & Hers Health, Inc. (NYSE:HIMS), the maker and distributor of generic medicines, is one of the most notable names in this bucket. The stock has been rocked after reporting Q2 results, primarily on concerns that its revenue projections for its GLP-1 weight loss compounds are over ...